Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSURE
NCT03871517Phase 4Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2019
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Indobufen in ischemic stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Any new stroke event (ischemic stroke or hemorrhagic stroke) at 3 months and Severe or moderate bleeding at 3 months. Started Jun 2019; status: completed.
02
Drugs
Indobufen
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03871517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871517.